FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1Preeti Narayan, Julia A. Beaver, Shenghui Tang et al.|Clinical Cancer Research|2020Cited by 185
U.S. FDA Drug Approvals for Breast Cancer: A Decade in ReviewShaily Arora, Julia A. Beaver, Preeti Narayan et al.|Clinical Cancer Research|2021Cited by 73
U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in ReviewShaily Arora, Julia A. Beaver, Preeti Narayan et al.|Clinical Cancer Research|2021Cited by 23